Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product la...
Merck & Co., Inc. (NYSE:MRK) reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield.
T
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion. The c...
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion. The co...
Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral HIV regimen and its plans for a monthly oral pre-exposure prophylaxis, or PrEP, candidate.
Comp
Global pharmaceutical company Merck (NYSE:MRK) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know. Merck...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
